Completed PHASE3 INTERVENTIONAL 2-arm NCT00578695

THE BALANCE Study: Treatment of Hyponatremia Based on Lixivaptan in NYHA Class III/IV Cardiac Patient Evaluation

Sponsor: Biogen

Updated 8 times since 2017 Last updated: Jun 20, 2011 Started: Jan 31, 2007 Primary completion: Jun 30, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Hyponatremia, this trial is completed. The trial is conducted by Biogen and has accumulated 8 data snapshots since 2007. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Apr 2022 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — Apr 2022 [monthly]

Completed PHASE3

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Jan 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Biogen
CardioKine Inc.
Cardiokine Biopharma, LLC

Data source: CardioKine Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Amarillo, United States , Antofagasta, Chile , Atlanta, United States , Aurora, United States , Bad Krozingen, Germany , Bad Nauheim, Germany , Bad Segeberg, Germany , Bakersfield, United States , Baltimore, United States , Bangalore, India and 199 more locations